Sansure Biotech Inc. (688289.SS)
CNY 22.2
(0.0%)
CNY 22.2
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 638.67 Million CNY | -49.4% |
| 2022 | 1.26 Billion CNY | 89.26% |
| 2021 | 666.89 Million CNY | -2.05% |
| 2020 | 680.87 Million CNY | 260.9% |
| 2019 | 188.66 Million CNY | 15.22% |
| 2018 | 163.74 Million CNY | 28.82% |
| 2017 | 127.11 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 230.98 Million CNY | -0.91% |
| 2024 Q2 | 185 Million CNY | -19.9% |
| 2024 Q3 | 236.46 Million CNY | 14.63% |
| 2023 Q2 | 175.71 Million CNY | 112.36% |
| 2023 FY | 638.67 Million CNY | -49.4% |
| 2023 Q1 | 82.74 Million CNY | -87.32% |
| 2023 Q3 | 168.45 Million CNY | -4.13% |
| 2023 Q4 | 233.1 Million CNY | 38.38% |
| 2022 Q4 | 652.75 Million CNY | 147.95% |
| 2022 Q2 | 200.02 Million CNY | 36.9% |
| 2022 Q1 | 146.1 Million CNY | -37.55% |
| 2022 Q3 | 263.26 Million CNY | 31.62% |
| 2022 FY | 1.26 Billion CNY | 89.26% |
| 2021 Q1 | 135.93 Million CNY | 3.28% |
| 2021 Q2 | 108.6 Million CNY | -20.11% |
| 2021 FY | 666.89 Million CNY | -2.05% |
| 2021 Q4 | 233.97 Million CNY | 24.2% |
| 2021 Q3 | 188.38 Million CNY | 73.45% |
| 2020 FY | 680.87 Million CNY | 260.9% |
| 2020 Q4 | 131.62 Million CNY | -52.44% |
| 2020 Q1 | 89.26 Million CNY | 64.68% |
| 2020 Q2 | 183.2 Million CNY | 105.23% |
| 2020 Q3 | 276.78 Million CNY | 51.08% |
| 2019 FY | 188.66 Million CNY | 15.22% |
| 2019 Q3 | 44.61 Million CNY | 1.2% |
| 2019 Q2 | 44.08 Million CNY | -3.65% |
| 2019 Q1 | 45.75 Million CNY | 0.0% |
| 2019 Q4 | 54.2 Million CNY | 21.49% |
| 2018 FY | 163.74 Million CNY | 28.82% |
| 2017 FY | 127.11 Million CNY | 0.0% |